Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Cordis said the FDA cleared its SELUTION SLR drug-eluting balloon to treat coronary in-stent restenosis in the US. The company said it is the first sirolimus drug-eluting balloon cleared in the US. In the SELUTION4ISR trial of more than 400 patients, the 12-month non-inferiority endpoint was met, with target lesion fai
Cordis announced the FDA has approved its SELUTION SLR™ Drug-Eluting Balloon for treating coronary in-stent restenosis, marking the first sirolimus drug-eluting balloon available in the U.S. This device delivers sustained sirolimus therapy without a permanent implant.